Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of “Buy” by Brokerages

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has been given a consensus rating of “Buy” by the seven brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $29.25.

A number of equities research analysts have recently weighed in on EYPT shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Thursday, January 22nd. Cantor Fitzgerald raised shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, November 25th. TD Cowen raised shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Friday, December 19th. Royal Bank Of Canada raised their target price on shares of Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Finally, Mizuho set a $28.00 price target on shares of Eyepoint Pharmaceuticals in a research report on Monday, October 20th.

Insider Activity

In related news, insider Ramiro Ribeiro sold 42,544 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $17.10, for a total value of $727,502.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.46% of the company’s stock.

Institutional Trading of Eyepoint Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Janney Montgomery Scott LLC bought a new position in Eyepoint Pharmaceuticals in the second quarter valued at approximately $114,000. R Squared Ltd acquired a new stake in shares of Eyepoint Pharmaceuticals in the 2nd quarter valued at $100,000. Nisa Investment Advisors LLC increased its stake in shares of Eyepoint Pharmaceuticals by 1,636.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,900 shares of the company’s stock valued at $27,000 after purchasing an additional 2,733 shares during the last quarter. Franklin Resources Inc. increased its stake in shares of Eyepoint Pharmaceuticals by 3.6% in the 2nd quarter. Franklin Resources Inc. now owns 4,301,123 shares of the company’s stock valued at $40,474,000 after purchasing an additional 151,262 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of Eyepoint Pharmaceuticals by 11.0% during the 2nd quarter. Rhumbline Advisers now owns 96,280 shares of the company’s stock worth $906,000 after buying an additional 9,548 shares in the last quarter. Institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Trading Down 0.5%

Eyepoint Pharmaceuticals stock opened at $12.94 on Monday. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -4.33 and a beta of 1.76. Eyepoint Pharmaceuticals has a 12 month low of $3.91 and a 12 month high of $19.11. The stock’s 50 day moving average is $15.95 and its 200-day moving average is $13.78.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.